Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2000-11-29
2004-03-30
Mosher, Mary E. (Department: 1642)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C435S002000, C435S372000, C424S534000, C424S093700
Reexamination Certificate
active
06713056
ABSTRACT:
The present invention relates to a new combined preparation for the treatment of neoplasic diseases or of infectious diseases.
The present invention describes sequences of conventional treatments of cancer or infections and of immunotherapies reversing or preventing chemoresistance and allowing long lasting therapeutic responses.
BACKGROUND OF THE INVENTION
In conventional therapy, residual tumor cells or infectious agents are left undamaged due to chemoresistance or due to the fact that these cells are shaded in protected areas or located in hypoxic areas poorly vascularized and not accessible to conventional treatments. The genetic instability and heterogeneity of tumors and micro-organisms indeed allow them to adapt and to develop resistance to therapies.
The beneficial effects of chemotherapy can be compromised by cellular mechanisms that allow infectious agents or neoplasic tissue to evade the toxicity of drugs. In some cases, pleiotropic resistance to a variety of unrelated drugs has been observed, and this phenomenon has been called multidrug resistance.
Resistance to chemotherapy, whether it is intrinsic or acquired, is a major cause of failure in the curative treatment of chronic infections or neoplasic malignancies. Among the most active anti-cancer agents used in the treatment of haematological malignancies are some natural toxin-derived drugs, such as the anthracycline daunorubicin or adriamicin, the epipodophyllotoxins, taxoter derivatives, the vinca alkaloid vincristine, cisplatin, fluorouracils.
Development of cross-resistance to these structurally and functionally unrelated drugs, called multidrug resistance, is frequently observed in second or third intention cytotoxic treatment of cancer.
Multiple drug resistance of infectious agents and particularly of bacteria to antibiotics such as penicillins, &bgr;-lactamines, cephalosporines, aminoglucosides, macrolides and sulfamides, is more and more often seen in hospitals.
Monocyte derived cells (MDCs) are immune cells such as obtained by culture of blood mononuclear cells in non adherent gas permeable plastic or Teflon bags for 5 to 10 days at 37° C. in O
2
/CO
2
atmosphere. Their culture medium (RPMI, IMDM, AIM5 (Gibco) or X-VIVO (Biowhittaker)) contains eventually cytokines or ligands as defined in patents PCT/EP93/01232, WO94/26875 or EP 97/02703 or in the articles mentioned below:
“Autologous lymphocytes prevent the death of monocytes in culture and promote, as do GM-CSF, IL-3 and M-CSF, their differentiation into macrophages”. (Lopez M., Martinache Ch., Canepa S., Chokri M., Scotto F., Bartholeyns J.; J. of Immunological Methods, 159: 29-38, 1993);
“Immune therapy with macrophages: Present status and critical requirements for implementation” (Bartholeyns J., Romet-Lemonne J-L., Chokri M., Lopez M.; Immunobiol., 195: 550-562, 1996);
“In vitro generation of CD83
+
human blood dendritic cells for active tumor immunotherapy” (Thurnher M., Papesh C., Ramoner R., Gastlt G. and al.; Experimental Hematology, 25: 232-237, 1997);
“Dendritic cells as adjuvants for immune-mediated resistance to tumors” (Schuler G. and Steinman R. M.; J. Exp. Med., 186: 1183-1187, 1997).
All these patents applications and articles are included herein for references.
They can be activated by IFN-&ggr; at the end of culture to obtain in particular cytotoxic macrophages. They can be centrifuged to be concentrated and purified before resuspension in isotonic solution.
Monocyte derived cells (MDCs) can either be killer macrophages, phagocytozing cells, growth factors and cytokines releasing cells, or dendritic cells according to their conditions of differentiation. Dendritic cells can for example be obtained as described in “In vitro generation of CD83
+
human blood dendritic cells for active tumor immunotherapy” (Thurnher M., Papesh C., Ramoner R., Gastlt G. and al.; Experimental Hematology, 25: 232-237, 1997) and “Dendritic cells as adjuvants for immune-mediated resistance to tumors” (Schuler G. and Steinman R. M.; J. Exp. Med., 186: 1183-1187, 1997), and EP 97/02703.
In addition, activated monocyte derived cells (macrophages) can be used to deliver therapeutic agents to tumor or infectious sites.
BRIEF SUMMARY OF THE INVENTION
One of the aims of the invention is to provide a combined preparation of active substances under the form of individual components for the simultaneous separate or sequential use, in the treatment of cancer or of infectious diseases.
Another aim of the invention is to provide a method for the treatment of residual cancer resistant to chemotherapy.
Another aim of the invention is to provide a method for the treatment of infectious diseases resistant to antibiotic treatment.
The invention relates to a combined preparation containing, as active substance, the following individual components, in the form of a kit-of-parts:
monocyte derived cells, particularly cytotoxic macrophages,
chemotherapy or immunotherapy drugs,
for the simultaneous, separate or sequential use, for the treatment of cancer or infectious diseases.
REFERENCES:
patent: WO 96/22781 (1996-08-01), None
Fidler and Kleinerman, J. Clin. Oncol., 1984, 2:937-943.*
Silagi, et al., Int J Cancer, 1988, 41:315-322.*
Schachter, et al., 1998, Cancer biotherapy and Radiopharmaceuticals 13: 155-164.*
Williams, et al., 1997, Br J Haematol, 98(4):960-8.*
By B. Hennemann et al., “Monocyte/Macrophage Activation by Immunostimulators: Role in Cancer Therapy”,Clinical Immunotherapeutics, 1996, pp. 294-308.
By B. Hennemann et al., “Adoptive Immunotherapy with Tumor-Cytotoxic Macrophages Dervied from Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhuGM-CSF) Mobilized Peripheral Blood Monocytes”,Journal of Immunotherapy, 1997, pp. 365-361.
By J. Bartoleyns et al., “Immune Therapy with Macrophages: Present Status and Critical Requirements for Implementation”,Immunology, 1996, pp. 550550-562.
By T. Takeda et al., “The effect of local immunotherapy for breast cancer using a mixture of OK-432 and fibrinogen supplemented with activated macrophages”,Biotherapy, 1994, pp. 47-54.
Bartholeyns Jacques
Fouron Yves
Romet-Lemonne Jean-Loup
I.D.M. Immuno-Designed Molecules
Mosher Mary E.
Yu Misook
LandOfFree
Combined preparation for the treatment of neoplasic diseases... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combined preparation for the treatment of neoplasic diseases..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined preparation for the treatment of neoplasic diseases... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3217951